All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
ACR 2025 | Top abstracts: What’s hot in lupus?
To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2025, October 24–29, 2025, Chicago, US, the Lupus Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lupus.
| Oral presentations: Sunday, October 26 | |||
| Abstract | Title | Presenter | Time (CDT) |
| 0801 | Achieving sustained lupus low disease activity state and remission with Ianalumab (VAY736) in patients with systemic lupus erythematosus: A post hoc analysis from a phase II study | Ed Vital | 13:00–13:15 |
| 0802 | Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: Pooled post-hoc exploratory analysis from a randomized placebo-controlled phase II study | Eric Morand | 13:15–13:30 |
| 0803 | Improved efficacy and safety outcomes in patients with SLE treated with belimumab (BEL) versus immunosuppressants (IS), in addition to antimalarials (AM) and glucocorticoids (GC): A post hoc summary of five phase 3 trials | Mariele Gatto | 13:30–13:45 |
| Oral presentations: Wednesday, October 29 | |||
| Abstract | Title | Presenter | Time (CDT) |
| 2650 | LFA-REAL outperforms SLEDAI and BILAG in detecting clinical change in lupus activity | Alberto Nordmann-Gomes | 10:45–11:00 |
| 2694 | Effect of deucravacitinib treatment on renal dysfunction–associated plasma biomarkers from a phase 2 study in patients with systemic lupus erythematosus | Amit Saxena | 11:45–12:00 |
| 2696 | Biomarker data from an open-label, phase 1/2 study for YTB323 (rapcabtagene autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B cell compartment in severe refractory SLE | Eric Morand | 12:15–12:30 |
| Posters | |||
| Abstract | Title | Presenter | Date and time (CDT) |
| 0640 | Impact of clinically important improvements in patient-reported outcomes on disease activity in patients with systemic lupus erythematosus treated with upadacitinib or placebo: Results from the phase 2 SLEek study | Vibeke Strand | Sunday, October 26, 10:30–12:30 |
| 0645 | Achievement of low disease activity and remission in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-week results from a phase 3 trial | Eric Morand | Sunday, October 26, 10:30–12:30 |
| 0650 | Obinutuzumab demonstrates steroid-sparing effects and consistent benefit in patients with lupus nephritis when using multiple primary endpoint definitions: A secondary analysis of phase III trial results | Brad Rovin | Sunday, October 26, 10:30–12:30 |
| 1519 | Post-hoc analysis of sustained response over time in systemic lupus erythematosus patients treated with cenerimod in CARE (phase 2 B) study | Anca Askanase
| Monday, October 27, 10:30–12:30 |
| 1529 | Updated phase 1 trial data assessing the tolerability, efficacy, pharmacokinetics, and pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed chimeric antigen receptor t cell therapy using a next-generation process for severe, refractory SLE | Georg Schett | Monday, October 27, 10:30–12:30 |
| 1532 | Preliminary safety, efficacy, and cellular kinetics of CTA313, a CD19/BCMA dual-targeted universal CAR-T therapy, for active systemic lupus erythematosus | Jan Davidson-Moncada | Monday, October 27, 10:30–12:30 |
| 1545 | Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: Interim analysis of a phase 3 randomized placebo-controlled study | Susan Manzi | Monday, October 27, 10:30–12:30 |
| 2445 | Achievement of treat to target measures with upadacitinib in patients with systemic lupus erythematosus: Phase 2 randomized sleek clinical trial results | Eric Morand | Tuesday, October 28, 10:30–12:30 |
| 2458 | Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients (pts) with severe, refractory systemic lupus erythematosus (srSLE): Preliminary results from the phase I CARLYSLE study | Maria Leandro | Tuesday, October 28, 10:30–12:30 |
| 2464 | IMC-002 (IMM0306), a first-in-class bi-specific fusion protein, demonstrates improvements in systemic lupus erythematosus (SLE) disease activity measures and biomarkers in patients with moderate to severe active SLE in the Open-label phase 1b/2 study | Qian Zheng | Tuesday, October 28, 10:30–12:30 |
| 2465 | CD19/BCMA dual-targeting FasTCAR-T cells GC012F (AZD0120) in patients with refractory systemic lupus erythematosus: An open-label, single-center phase I study | Qiong Fu | Tuesday, October 28, 10:30–12:30 |
| 2466 | Efficacy and safety results of zetomipzomib from the PALIZADE phase 2b clinical trial in patients with lupus nephritis | Richard A. Furie | Tuesday, October 28, 10:30–12:30 |
| 2468 | RESET-SLE: Clinical trial evaluating rese-cel (Resecabtagene Autoleucel), a fully human, autologous 4-1BB CD19-CAR T cell therapy in non-renal SLE and lupus nephritis | Saira Sheikh | Tuesday, October 28, 10:30–12:30 |
| LB10 | Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: Results from a phase 2 program | Eric Morand | Tuesday, October 28, 10:30–12:30 |
| LB13 | Obinutuzumab leads to deep B-cell depletion in the kidney parenchyma of patients with lupus nephritis: An exploratory analysis of the REGENCY trial | Brad H. Rovin | Tuesday, October 28, 10:30–12:30 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content